ArticleInflammatory bowel diseases2014
Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease.
Article in Inflammatory bowel diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Diagnostic Value of Neutrophil CD64 Index in Diabetic Foot Osteomyelitis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- CD64 as novel molecular imaging marker for the characterization of synovitis in rheumatoid arthritis.Arthritis research & therapy · 2023Article
- Transcriptome analysis in acute gastrointestinal graft-Haematologica · 2023Article
- Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2023Article
- Finding the sweet spot: glycosylation mediated regulation of intestinal inflammation.Mucosal immunology · 2022Review
- Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases.Precision clinical medicine · 2021Review
- Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.Inflammatory bowel diseases · 2021Article
- Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.Pharmaceutics · 2021Article
- Identification of "antigen-specific" neutrophils in atherosclerosis patients that compromise vascular endothelial barrier function.American journal of translational research · 2020Article
- Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab.Crohn's & colitis 360 · 2019Article
- Redefining the Practical Utility of Blood Transcriptome Biomarkers in Inflammatory Bowel Diseases.Journal of Crohn's & colitis · 2019Article
- Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease.Clinical and experimental immunology · 2019Article
- Long ncRNA Landscape in the Ileum of Treatment-Naive Early-Onset Crohn Disease.Inflammatory bowel diseases · 2018Observational
- Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.Inflammatory bowel diseases · 2017Article
- A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy.Inflammatory bowel diseases · 2016Article
- Inflammatory Bowel Disease in Children and Adolescents.JAMA pediatrics · 2015Review
- Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis.Immunity · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 14 institutions in 2 countries.
Funding
Abstract
backgroundNeutrophil expression of the Fcγ receptor I (CD64) is upregulated in adult patients with clinically active inflammatory bowel disease (IBD). We tested the relationship of CD64 with mucosal inflammation and clinical relapse in pediatric Crohn's disease (CD).
methodsIn a cohort of 208 newly diagnosed CD and 43 non-IBD controls, ileal expression of FcγRI/S100A9 was determined by RNA sequencing from biopsies obtained at ileocolonoscopy. In a second cohort, we tested for the peripheral blood polymorphonuclear neutrophil (PMN) CD64 index from 26 newly diagnosed CD, 30 non-IBD controls, and 83 children with established CD.
resultsIleal FcγRIA mRNA expression was significantly elevated in CD at diagnosis compared with non-IBD controls (P < 0.001), and correlated with ileal S100A9 (calprotectin) expression (r = 0.83, P < 0.001). The median (range) PMN CD64 index for newly diagnosed CD was 2.3 (0.74-9.3) compared with 0.76 (0.39-1.2) for non-IBD controls (P < 0.001) with 96% sensitivity and 90% specificity at the cut point of 1.0. The PMN CD64 index significantly correlated with mucosal injury as measured by the simple endoscopic score for CD (r = 0.62, P < 0.001). Patients with CD in clinical remission receiving maintenance therapy with a PMN CD64 index <1.0 had a sustained remission rate of 95% over the following 12 months compared with 56% in those with a PMN CD64 index >1.0 (P < 0.01).
conclusionsAn elevated PMN CD64 index is associated with both mucosal inflammation and an increased risk for clinical relapse in pediatric CD. The PMN CD64 index is a reliable marker for sustained remission in patients with CD receiving maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.